Ontology highlight
ABSTRACT:
SUBMITTER: Rauzan M
PROVIDER: S-EPMC5354438 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Rauzan Muhammad M Chuah Charles T H CT Ko Tun Kiat TK Ong S Tiong ST
PloS one 20170316 3
Chronic myeloid leukemia (CML) treatment has been improved by tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) but various factors can cause TKI resistance in patients with CML. One factor which contributes to TKI resistance is a germline intronic deletion polymorphism in the BCL2-like 11 (BIM) gene which impairs the expression of pro-apoptotic splice isoforms of BIM. SB939 (pracinostat) is a hydroxamic acid based HDAC inhibitor with favorable pharmacokinetic, physicochemical and ...[more]